MEDVidi Review
GLP-1 weight-loss telehealth · Independently scored 6.6/10
Best for: people who want a licensed provider to prescribe brand glp-1 they fill with insurance
MEDVidi is a solid telehealth option with balanced features and pricing.
What the monthly price covers
Medication
Billed separately
Provider visits
Included
Shipping
Billed separately
Lab work
Not disclosed
Coaching
Not disclosed
No insurance needed · Vetted by our editors
MEDVidi is a US telehealth platform whose licensed providers evaluate patients and prescribe GLP-1 weight-management medications, including brand-name Zepbound (tirzepatide) and Wegovy (semaglutide), plus Saxenda, Qsymia and phentermine. It runs on a per-visit consult model rather than a bundled subscription: an initial appointment is 195 dollars and a follow-up is 159 dollars, and prescriptions go to the patient's chosen pharmacy, so medication cost is separate. MEDVidi operates in 33 states. This is a distinct brand from MEDVi (medvi.com).
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
Vetted alternatives to MEDVidi
MEDVi
Best for: patients who want the option to switch between compounded and brand-name GLP-1 through one provider
Editorial score · methodology
Liv Body
Best for: compounded GLP-1 paired with a muscle-preservation supplement stack
Editorial score · methodology
DudeMeds
Best for: men seeking no-fee GLP-1 access with oral and injectable options
Editorial score · methodology
MEDVidi at a glance
- Type
- GLP-1 telehealth provider
- Medications
- Semaglutide, Tirzepatide, Zepbound, Wegovy
- Pricing model
- Flat — dose increases don't raise the monthly price
- What's included
- Consult
- FDA status
- No FDA warning letter on record
How we scored MEDVidi
Each dimension is scored algorithmically from MEDVidi’s real pricing, drugs offered, verification status, and disclosed inclusions — using the same six-dimension framework we apply to every provider.
Value25%
6.2/10MEDVidi does not post a standard monthly cash price up front, so cost transparency is limited — confirm the ongoing rate before you commit. Pricing is flat across doses, so there is no escalation markup as you titrate up.
Effectiveness25%
7.6/10MEDVidi offers both semaglutide and tirzepatide — the two GLP-1 molecules with the strongest published weight-loss trial outcomes.
User Experience15%
6.9/10Online intake and platform experience — consult included in the price; 6 platform features disclosed.
Trust & Safety15%
6.8/10Core details confirmed by our editors; no FDA warning letters on file (last checked 2026-07-16).
Accessibility10%
5.6/10MEDVidi's exact state footprint isn't published — confirm coverage in your state before signing up.
Support10%
5.4/10MEDVidi provides standard clinician follow-up; no extended coaching or community program is disclosed.
Providers that don’t post pricing up front score lower on Value and carry a cost-transparency note in their review. Read the full methodology →
How we verified this MEDVidi review
Last checked July 2026- Confirmed what the monthly price does and doesn't include
- Checked the FDA warning-letter database for enforcement actions
- Walked the public intake/checkout flow on the provider's site
Pricing, availability, and compliance facts come from the provider's own site and primary regulatory records — see the sources below. Editorial confidence in this data: medium.
GLP-1 medications MEDVidi offers
Tap any medication to read our plain-English guide — how it works, dosing, side effects, and what the trials found.
What we like
- Licensed providers can prescribe brand-name Zepbound and Wegovy
- Transparent flat consultation fees (195 dollar initial, 159 dollar follow-up)
- Prescriptions sent to the patient's pharmacy of choice, so insurance can be used
Watch-outs
- Consult-fee model: medication is not included and its cost is separate
- No medication pricing is published
- State list is shown as a map rather than enumerated
Is MEDVidi worth it? Our verdict
MEDVidi positions itself around one thing: people who want a licensed provider to prescribe brand glp-1 they fill with insurance.
On top of the prescription itself, MEDVidi points to Zepbound, Wegovy, and Per-visit model.
How much MEDVidi actually costs
MEDVidi doesn't post a standard monthly cash price publicly. Start a consultation to get an exact quote, and confirm the ongoing rate — not just any first-month offer — before you commit.
Medications: what MEDVidi prescribes
MEDVidi prescribes semaglutide (the active drug in Wegovy and Ozempic) and tirzepatide (the active drug in Zepbound and Mounjaro) — the two most-studied weight-loss molecules on the market today.
Who MEDVidi is best for — and who should skip it
A good fit if you…
- want a straightforward telehealth GLP-1 program.
Look elsewhere if you…
- specifically want an FDA-approved brand-name pen.
- need to bill insurance — like most of this market, it's cash-pay.
Trust, safety, and medical oversight
We found no FDA warning letters on file for the provider. We explain how we weigh medical oversight and compliance in our scoring methodology.
Bottom line
MEDVidi could be worth a look, but it doesn't publish a standard price up front — get a quote and confirm the ongoing rate before deciding, and compare it against the alternatives below. If you're comparison-shopping, Sesame Care is one of the closest alternatives we track — worth a look before deciding.
The Bottom Line
MEDVidi is a solid telehealth option with balanced features and pricing.
Ready to start with MEDVidi?
See current pricing and start your free consultation.
MEDVidi might not be your best fit if…
We rank editorially, so here’s where a different provider we track may serve you better.
Frequently Asked Questions
Key terms, explained
New to GLP-1s? Tap any term for a quick, plain-English definition.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Sources
The primary regulatory filings and peer-reviewed studies cited throughout this MEDVidi review:
Sources & methodology — as of July 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
See MEDVidi's current pricing
Start your free consultation to check eligibility and today's price.